Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Background: The CheckMate 227 trial has indicated that nivolumab plus ipilimumab compared with chemotherapy significantly increases long-term survival in the first-line setting of advanced non-small-cell lung cancer (NSCLC).Methods: A Markov model was built to estimate the cost and effectiveness of...

Full description

Bibliographic Details
Main Authors: Huabin Hu, Longjiang She, Mengting Liao, Yin Shi, Linli Yao, Dong Ding, Youwen Zhu, Shan Zeng, David P. Carbone, Jin Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness
nivolumab
ipilimumab
chemotherapy
non-small cell lung cancer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01649/full

Similar Items

Similar Items